P2X1 receptor-mediated inhibition of the proliferation of human coronary smooth muscle cells involving the transcription factor NR4A1

Purinergic Signalling

Volumn 9, Issue 4, 2013, Pages 677-686

  Hinze, Annette Viktoria ^a,b   Mayer, Peter ^a   Harst, Anja ^a   von Kügelgen, Ivar ^b  

^a FEDERAL INSTITUTE FOR DRUGS AND MEDICAL DEVICES   (Germany)

^b UNIVERSITY OF BONN   (Germany)

Author keywords

Coronary artery; Early growth response factor; Migration; Nuclear factor NR4A1; Proliferation

Indexed keywords

ALPHA, BETA METHYLENEADENOSINE TRIPHOSPHATE; BETA, GAMMA METHYLENEADENOSINE TRIPHOSPHATE; MESSENGER RNA; NUCLEAR RECEPTOR NUR77; PLATELET DERIVED GROWTH FACTOR; PURINERGIC P2X1 RECEPTOR; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; NR4A1 PROTEIN, HUMAN; TRANSCRIPTION FACTOR;

ARTICLE; CELL GROWTH; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; CORONARY ARTERY; GENE EXPRESSION; GENE SILENCING; GROWTH INHIBITION; HUMAN; HUMAN CELL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SMOOTH MUSCLE FIBER; ADULT; CELL CULTURE; CORONARY BLOOD VESSEL; CYTOLOGY; FEMALE; METABOLISM; MIDDLE AGED; VASCULAR SMOOTH MUSCLE;

ADULT; CELL PROLIFERATION; CELLS, CULTURED; CORONARY VESSELS; FEMALE; HUMANS; MIDDLE AGED; MUSCLE, SMOOTH, VASCULAR; NUCLEAR RECEPTOR SUBFAMILY 4, GROUP A, MEMBER 1; RECEPTORS, PURINERGIC P2X1; TRANSCRIPTION FACTORS;

EID: 84890553440     PISSN: 15739538     EISSN: 15739546     Source Type: Journal    
DOI: 10.1007/s11302-013-9380-5     Document Type: Article

References (63)

1. von Kügelgen I, Starke K (1985) Noradrenaline and adenosine triphosphate as co-transmitters of neurogenic vasoconstriction in rabbit mesenteric artery. J Physiol 367: 435-455.
2. Burnstock G, Kennedy C (1986) A dual function for adenosine 5'-triphosphate in the regulation of vascular tone. Excitatory cotransmitter with noradrenaline from perivascular nerves and locally released inhibitory intravascular agent. Circ Res 58: 319-330.
3. Burnstock G (1990) Noradrenaline and ATP as co-transmitters in sympathetic nerves. Neurochem Int 17: 357-368.
4. von Kügelgen I, Starke K (1991) Noradrenaline-ATP co-transmission in the sympathetic nervous system. Trends Pharmacol Sci 12: 319-324.
5. Erlinge D, Burnstock G (2008) P2 receptors in cardiovascular regulation and disease. Purinergic Signal 4: 1-20. doi: 10. 1007/s11302-007-9078-7.
6. Olsson RA, Pearson JD (1990) Cardiovascular purinoceptors. Physiol Rev 70: 761-845.
7. Ralevic V, Burnstock G (1991) Roles of P2-purinoceptors in the cardiovascular system. Circulation 84: 1-14.
8. Ralevic V, Burnstock G (1998) Receptors for purines and pyrimidines. Pharmacol Rev 50: 413-492.
9. Schuchardt M, Tölle M, van der Giet M (2012) P2Y purinoceptors as potential emerging therapeutical target in vascular disease. Curr Pharm Des 18: 6169-6180.
10. Teuscher E, Weidlich V (1985) Adenosine nucleotides, adenosine, and adenine as angiogenesis factors. Biomed Biochim Acta 44: 493-495.
11. Erlinge D, Yoo H, Edvinsson L, Reis DJ, Wahlestedt C (1993) Mitogenic effects of ATP on vascular smooth muscle cells versus other growth factors and sympathetic co-transmitters. Am J Physiol 265: H1089-H1097.
12. Dubey RK, Gillespie DG, Osaka K, Suzuki F, Jackson EK (1996) Adenosine inhibits growth of rat aortic smooth muscle cells. Possible role of A2B receptor. Hypertension 27: 786-793.
13. Dubey RK, Gillespie DG, Mi Z, Jackson EK (1998) Adenosine inhibits growth of human aortic smooth muscle cells via A2B receptors. Hypertension 31: 516-521.
14. 1 adenosine receptor activation promotes angiogenesis and release of VEGF from monocytes. Circ Res 101: 1130-1138.
15. Ryzhov S, McCaleb JL, Goldstein AE, Biaggioni I, Feoktistov I (2007) Role of adenosine receptors in the regulation of angiogenic factors and neovascularization in hypoxia. J Pharmacol Exp Ther 320: 565-572.
16. Burnstock G, Verkhratsky A (2010) Long-term (trophic) purinergic signaling: purinoceptors control cell proliferation, differentiation, and death. Cell Death Dis 1: e9. doi: 10. 1038/cddis. 2009.
17. 2B receptors. Am J Physiol Heart Circ Physiol 301: H391-H401. doi: 10. 1152/ajpheart. 00336. 2011.
18. Dubey RK, Rosselli M, Gillespie DG, Mi Z, Jackson EK (2010) Extracellular 3', 5'-cAMP-adenosine pathway inhibits glomerular mesangial cell growth. J Pharmacol Exp Ther 333: 808-815. doi: 10. 1124/jpet. 110. 166371.
19. Jackson EK, Ren J, Gillespie DG, Dubey RK (2010) Extracellular 2', 3'-cyclic adenosine 5'-monophosphate is a potent inhibitor of preglomerular vascular smooth muscle cell and mesangial cell growth. Hypertension 56: 151-158. doi: 10. 1161/HYPERTENSIONAHA. 110. 152454.
20. 2B receptors mediate the induction of early genes and inhibition of arterial smooth muscle cell proliferation via Epac. Cardiovasc Res 90: 148-156. doi: 10. 1093/cvr/cvq371.
21. Bonta PI, Pols TW, de Vries CJ (2007) NR4A nuclear receptors in atherosclerosis and vein-graft disease. Trends Cardiovasc Med 17: 105-111.
22. Arkenbout EK, de Waard V, van Bragt M, van Achterberg TA, Grimbergen JM, Pichon B, Pannekoek H, de Vries CJ (2002) Protective function of transcription factor TR3 orphan receptor in atherogenesis: decreased lesion formation in carotid artery ligation model in TR3 transgenic mice. Circulation 106: 1530-1535.
23. de Waard V, Arkenbout EK, Vos M, Mocking A, Niessen HWM, Stooker W, de Mol B, Quax P, Bakker E, van Bavel E, Pannekoek H, de Vries CJM (2006) TR3 nuclear orphan receptor prevents cyclic stretch-induced proliferation of venous smooth muscle cells. Am J Pathol 168: 2027-2035.
24. Pires NM, Pols TW, de Vries MR, van Tiel CM, Bonta PI, Vos M, Arkenbout EK, Pannekoek H, Jukema JW, Quax PH, de Vries CJ (2007) Activation of nuclear receptor Nur77 by 6-mercaptopurine protects against neointima formation. Circulation 115: 493-500.
25. Hinze AV, Mayer P, Harst A, von Kügelgen I (2012) Adenosine A3 receptor-induced proliferation of primary human coronary smooth muscle cells involving the induction of early growth response genes. J Mol Cell Cardiol 53: 639-645. doi: 10. 1016/j. yjmcc. 2012. 08. 003.
26. Khakh BS, Burnstock G, Kennedy C, King BF, North RA, Séguéla P, Voigt M, Humphrey PP (2001) International union of pharmacology. XXIV. Current status of the nomenclature and properties of P2X receptors and their subunits. Pharmacol Rev 53: 107-118.
27. Vial C, Roberts JA, Evans RJ (2004) Molecular properties of ATP-gated P2X receptor ion channels. Trends Pharmacol Sci 25: 487-493.
28. Gever JR, Cockayne DA, Dillon MP, Burnstock G, Ford AP (2006) Pharmacology of P2X channels. Pflugers Arch 452: 513-537.
29. Erlinge D, You J, Wahlestedt C, Edvinsson L (1995) Characterization of an ATP receptor mediating mitogenesis in vascular smooth muscle cells. Eur J Pharmacol 289: 135-149.
30. Erlinge D (1998) Extracellular ATP: a growth factor for vascular smooth muscle cells. Gen Pharmacol 31: 1-8.
31. Erlinge D, Hou M, Webb TE, Barnard EA, Möller S (1998) Phenotype changes of the vascular smooth muscle cell regulate P2 receptor expression as measured by quantitative RT-PCR. Biochem Biophys Res Commun 248: 864-870.
32. Wu SM, Fujiwara Y, Cibulsky SM, Clapham DE, Lien CL, Schultheiss TM, Orkin SH (2006) Developmental origin of a bipotential myocardial and smooth muscle cell precursor in the mammalian heart. Cell 127: 1137-1150.
33. Ohkubo S, Kumazawa K, Sagawa K, Kimura J, Matsuoka I (2001) Beta, gamma-methylene ATP-induced cAMP formation in C6Bu-1 cells: involvement of local metabolism and subsequent stimulation of adenosine A2B receptor. J Neurochem 76: 872-880.
34. Joseph SM, Pifer MA, Przybylski RJ, Dubyak GR (2004) Methylene ATP analogs as modulators of extracellular ATP metabolism and accumulation. Br J Pharmacol 142: 1002-1014.
35. Hinze AV, Harst A, Mayer P, von Kügelgen I (2011) P2X1 receptor-mediated inhibition of proliferation of primary human coronary smooth muscle cells via induction of NR4A1. Naunyn-Schmiedebergs Arch Pharmacol 383(Supplement 1): 1-11.
36. Hinze AV (2012) Purinorezeptor-vermittelte Änderung der Expression Proliferations-regelnder Gene in humanen Koronarglattmuskelzellen. Dissertation, University of Bonn.
37. von Kügelgen I, Harden TK (2011) Molecular pharmacology, physiology, and structure of the P2Y receptors. Adv Pharmacol 61: 373-415. doi: 10. 1016/B978-0-12-385526-8. 00012-6.
38. Hülsmann M, Nickel P, Kassack M, Schmalzing G, Lambrecht G, Markwardt F (2003) NF449, a novel picomolar potency antagonist at human P2X1 receptors. Eur J Pharmacol 470: 1-7.
39. Yan L, Bertarelli DC, Hayallah AM, Meyer H, Klotz KN, Müller CE (2006) A new synthesis of sulfonamides by aminolysis of p-nitrophenylsulfonates yielding potent and selective adenosine A2B receptor antagonists. J Med Chem 49: 4384-4391.
40. Nori S, Fumagalli L, Bo X, Bogdanov Y, Burnstock G (1998) Coexpression of mRNAs for P2X1, P2X2, and P2X4 receptors in rat vascular smooth muscle: an in situ hybridization and RT-PCR study. J Vasc Res 35: 179-185.
41. Kassack MU, Braun K, Ganso M, Ullmann H, Nickel P, Böing B, Müller G, Lambrecht G (2004) Structure-activity relationships of analogs of NF449 confirm NF449 as the most potent and selective known P2X1 receptor antagonist. Eur J Med Chem 39: 345-357.
42. Rettinger J, Braun K, Hochmann H, Kassack MU, Ullmann H, Nickel P, Schmalzing G, Lambrecht G (2005) Profiling at recombinant homomeric and heteromeric rat P2X receptors identifies the suramin analog NF449 as a highly potent P2X1 receptor antagonist. Neuropharmacology 48: 461-468.
43. Hechler B, Magnenat S, Zighetti ML, Kassack MU, Ullmann H, Cazenave JP, Evans R, Cattaneo M, Gachet C (2005) Inhibition of platelet functions and thrombosis through selective or nonselective inhibition of the platelet P2 receptors with increasing doses of NF449 [4, 4', 4', 4'-(carbonylbis(imino-5, 1, 3-benzenetriylbis-(carbonylimino)))tetrakis-benzene-1, 3-disulfonic acid octasodium salt]. J Pharmacol Exp Ther 314: 232-243.
44. Lewis CJ, Evans RJ (2000) Comparison of P2X receptors in rat mesenteric, basilar, and septal (coronary) arteries. J Auton Nerv Syst 81: 69-74.
45. Naito Y, Lowenstein JM (1985) 5'-nucleotidase from rat heart membranes. Inhibition by adenine nucleotides and related compounds. Biochem J 226: 645-651.
46. Schulze-Lohoff E, Zanner S, Ogilvie A, Sterzel RB (1995) Vasoactive diadenosine polyphosphates promote growth of cultured renal mesangial cells. Hypertension 26: 899-904.
47. Malam-Souley R, Seye C, Gadeau AP, Loirand G, Pillois X, Campan M, Pacaud P, Desgranges C (1996) Nucleotide receptor P2u partially mediates ATP-induced cell cycle progression of aortic smooth muscle cells. J Cell Physiol 166: 57-65.
48. Vonend O, Grote T, Oberhauser V, von Kügelgen I, Rump LC (2003) P2Y-receptors stimulating the proliferation of human mesangial cells through the MAPK42/44 pathway. Br J Pharmacol 139: 1119-1126.
49. Shen J, Seye CI, Wang M, Weisman GA, Wilden PA, Sturek M (2004) Cloning, upregulation, and mitogenic role of porcine P2Y2 receptor in coronary artery smooth muscle cells. Mol Pharmacol 66: 1265-1274.
50. Rauch BH, Rosenkranz AC, Ermler S, Böhm A, Driessen J, Fischer JW, Sugidachi A, Jakubowski JA, Schrör K (2010) Regulation of functionally active P2Y12 ADP receptors by thrombin in human smooth muscle cells and the presence of P2Y12 in carotid artery lesions. Arterioscler Thromb Vasc Biol 30: 2434-2442. doi: 10. 1161/ATVBAHA. 110. 213702.
51. Gui Y, He G, Walsh MP, Zheng XL (2011) Signaling mechanisms mediating uridine adenosine tetraphosphate-induced proliferation of human vascular smooth muscle cells. J Cardiovasc Pharmacol 58: 654-662. doi: 10. 1097/FJC. 0b013e318231e929.
52. Ginnan R, Sun LY, Schwarz JJ, Singer HA (2012) MEF2 is regulated by CaMKIIδ2 and a HDAC4-HDAC5 heterodimer in vascular smooth muscle cells. Biochem J 444: 105-114. doi: 10. 1042/BJ20120152.
53. Ruiz-Hurtado G, Morel E, Domínguez-Rodríguez A, Llach A, Lezoualc'h F, Benitah JP, Gomez AM (2012) Epac in cardiac calcium signaling. J Mol Cell Cardiol. doi: 10. 1016/j. yjmcc. 2012. 11. 021, in press.
54. Chaulet H, Desgranges C, Renault MA, Dupuch F, Ezan G, Peiretti F, Loirand G, Pacaud P, Gadeau AP (2001) Extracellular nucleotides induce arterial smooth muscle cell migration via osteopontin. Circ Res 89: 772-778.
55. Pillois X, Chaulet H, Belloc I, Dupuch F, Desgranges C, Gadeau AP (2002) Nucleotide receptors involved in UTP-induced rat arterial smooth muscle cell migration. Circ Res 90: 678-681.
56. Yu N, Erb L, Shivaji R, Weisman GA, Seye CI (2008) Binding of the P2Y2 nucleotide receptor to filamin A regulates migration of vascular smooth muscle cells. Circ Res 102: 581-588. doi: 10. 1161/CIRCRESAHA. 107. 162271.
57. Harada K, Matsumoto Y, Umemura K (2011) Adenosine diphosphate receptor P2Y12-mediated migration of host smooth muscle-like cells and leukocytes in the development of transplant arteriosclerosis. Transplantation 92: 148-154. doi: 10. 1097/TP. 0b013e318221d407.
58. Morris GE, Nelson CP, Brighton PJ, Standen NB, Challiss RA, Willets JM (2012) Arrestins 2 and 3 differentially regulate ETA and P2Y2 receptor-mediated cell signaling and migration in arterial smooth muscle. Am J Physiol Cell Physiol 302: C723-C734. doi: 10. 1152/ajpcell. 00202. 2011.
59. Wiedon A, Tölle M, Bastine J, Schuchardt M, Huang T, Jankowski V, Jankowski J, Zidek W, van der Giet M (2012) Uridine adenosine tetraphosphate (Up4A) is a strong inductor of smooth muscle cell migration via activation of the P2Y2 receptor and cross-communication to the PDGF receptor. Biochem Biophys Res Commun 417: 1035-1040. doi: 10. 1016/j. bbrc. 2011. 12. 088.
60. Abele S, Weyand M, Wollin M, Hiemann NE, Harig F, Fischlein T, Ensminger SM (2006) Clopidogrel reduces the development of transplant arteriosclerosis. J Thorac Cardiovasc Surg 131: 1161-1166.
61. 12 independently from ADP but antagonizes ADP-induced receptor signaling and platelet aggregation. Thromb Haemost 7: 1556-1565. doi: 10. 1111/j. 1538-7836. 2009. 03527.
62. 12 receptor oligomers and partitions them out of lipid rafts. Proc Natl Acad Sci U S A 103: 11069-11074.
63. 12 receptor. J Thromb Haemost 6: 1908-1914. doi: 10. 1111/j. 1538-7836. 2008. 03136.